Hong Kong – ByteDance, the Shanghai‑based internet powerhouse behind TikTok, has successfully closed a $290 million fundraising round for its artificial‑intelligence drug‑discovery unit, Anew Labs. The round, led by HSG (formerly Sequoia China) together with IDG Capital and Hillhouse Investment, also saw 5Y Capital act as co‑lead investor.
Investor lineup and valuation
In addition to the lead firms, a group of other investors participated, including Gaorong Ventures, Primavera Venture Partners, Boyu Capital, strategic investor SBP Group, and the state‑backed Shanghai Future Industries Fund. The influx of capital brings Anew Labs’ post‑money valuation to $1.5 billion, according to sources familiar with the transaction.
Strategic spin‑off rationale
ByteDance spun off Anew Labs to give the biotech venture a management structure and industry focus that differ from the parent company’s core social‑media and e‑commerce operations. One source explained that AI‑driven drug discovery follows a distinct logic and requires specialized oversight, prompting the decision to separate the unit while still supporting its long‑term growth.
Despite the new financing, ByteDance will retain a 56 percent ownership stake in Anew Labs, ensuring continued strategic alignment while allowing the subsidiary greater operational flexibility.
Implications for the Chinese biotech sector
The sizable raise underscores growing investor confidence in AI‑enabled pharmaceutical research, a field that promises to accelerate drug development timelines and reduce costs. By attracting both domestic venture capital and state‑linked funds, Anew Labs joins a wave of Chinese biotech firms positioning themselves as global competitors in the race to harness machine learning for new medicines.
Industry observers note that the involvement of prominent investors such as Hillhouse and IDG Capital signals a broader trend of capital flowing into high‑tech health ventures, reflecting both market demand and government encouragement for innovation in life sciences.
Responses
ByteDance and the participating investors declined to comment further on the transaction, citing the private nature of the fundraising.
Analysts anticipate that the fresh capital will enable Anew Labs to expand its research pipelines, attract top scientific talent, and potentially bring new drug candidates to clinical trials more quickly. The move also highlights the increasingly blurred lines between technology firms and traditional biotech companies as AI becomes a core tool in drug discovery.
Original reporting: Appleton, WI News Feed (HLL/CB) — read the source article.
